These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group. Elie R; Rüther E; Farr I; Emilien G; Salinas E J Clin Psychiatry; 1999 Aug; 60(8):536-44. PubMed ID: 10485636 [TBL] [Abstract][Full Text] [Related]
3. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group. Hedner J; Yaeche R; Emilien G; Farr I; Salinas E Int J Geriatr Psychiatry; 2000 Aug; 15(8):704-12. PubMed ID: 10960882 [TBL] [Abstract][Full Text] [Related]
4. Enhancement of zaleplon oral bioavailability using optimized self-nano emulsifying drug delivery systems and its effect on sleep quality among a sample of psychiatric patients. Khalifa MKA; Salem HA; Shawky SM; Eassa HA; Elaidy AM Drug Deliv; 2019 Dec; 26(1):1243-1253. PubMed ID: 31752566 [TBL] [Abstract][Full Text] [Related]
5. Zaleplon: a review of its use in the treatment of insomnia. Dooley M; Plosker GL Drugs; 2000 Aug; 60(2):413-45. PubMed ID: 10983740 [TBL] [Abstract][Full Text] [Related]
6. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Zaleplon Clinical Study Group. Fry J; Scharf M; Mangano R; Fujimori M Int Clin Psychopharmacol; 2000 May; 15(3):141-52. PubMed ID: 10870872 [TBL] [Abstract][Full Text] [Related]
7. A double-blind, randomized, comparative study to evaluate the efficacy and safety of zaleplon versus zolpidem in shortening sleep latency in primary insomnia. Huang YS; Hsu SC; Liu SI; Chen CK Chang Gung Med J; 2011; 34(1):50-6. PubMed ID: 21392474 [TBL] [Abstract][Full Text] [Related]
8. Preference of insomniac patients between a single dose of zolpidem 10 mg versus zaleplon 10 mg. Allain H; Bentué-Ferrer D; Breton SL; Polard E; Gandon JM Hum Psychopharmacol; 2003 Jul; 18(5):369-74. PubMed ID: 12858323 [TBL] [Abstract][Full Text] [Related]
9. Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening. Zammit GK; Corser B; Doghramji K; Fry JM; James S; Krystal A; Mangano RM J Clin Sleep Med; 2006 Oct; 2(4):417-23. PubMed ID: 17557470 [TBL] [Abstract][Full Text] [Related]
11. Zaleplon: a pyrazolopyrimidine sedative-hypnotic agent for the treatment of insomnia. Weitzel KW; Wickman JM; Augustin SG; Strom JG Clin Ther; 2000 Nov; 22(11):1254-67. PubMed ID: 11117652 [TBL] [Abstract][Full Text] [Related]
12. Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. Rosenberg RP Ann Clin Psychiatry; 2006; 18(1):49-56. PubMed ID: 16517453 [TBL] [Abstract][Full Text] [Related]
13. Zaleplon for insomnia. Med Lett Drugs Ther; 1999 Oct; 41(1063):93-4. PubMed ID: 10535052 [No Abstract] [Full Text] [Related]
14. Zopiclone and zaleplon vs benzodiazepines in the treatment of insomnia: Canadian consensus statement. Montplaisir J; Hawa R; Moller H; Morin C; Fortin M; Matte J; Reinish L; Shapiro CM Hum Psychopharmacol; 2003 Jan; 18(1):29-38. PubMed ID: 12532313 [No Abstract] [Full Text] [Related]
15. Long-term use of sedative hypnotics in older patients with insomnia. Ancoli-Israel S; Richardson GS; Mangano RM; Jenkins L; Hall P; Jones WS Sleep Med; 2005 Mar; 6(2):107-13. PubMed ID: 15716214 [TBL] [Abstract][Full Text] [Related]
16. Noise-induced sleep maintenance insomnia: hypnotic and residual effects of zaleplon. Stone BM; Turner C; Mills SL; Paty I; Patat A; Darwish M; Danjou P Br J Clin Pharmacol; 2002 Feb; 53(2):196-202. PubMed ID: 11851645 [TBL] [Abstract][Full Text] [Related]
17. Management of insomnia--the role of zaleplon. Richardson GS; Roth T; Kramer JA MedGenMed; 2002 Mar; 4(1):9. PubMed ID: 11965211 [TBL] [Abstract][Full Text] [Related]
18. Safety of zaleplon in the treatment of insomnia. Israel AG; Kramer JA Ann Pharmacother; 2002 May; 36(5):852-9. PubMed ID: 11978165 [TBL] [Abstract][Full Text] [Related]
19. Benefit-risk assessment of zaleplon in the treatment of insomnia. Barbera J; Shapiro C Drug Saf; 2005; 28(4):301-18. PubMed ID: 15783240 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of zaleplon at peak plasma levels. Mangano RM Int J Clin Pract Suppl; 2001 Jan; (116):9-13. PubMed ID: 11219331 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]